Haematologica EWOG-MDS website
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanz, M.
Haematologica, Vol 90, Issue 9, 1231-1235
Copyright © 2005 by Ferrata Storti Foundation

Journal Article

Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence

MA Sanz, P Fenaux, F Lo Coco, and

University Tor Vertgata, Rome. msanz@uv.es

Recent studies have demonstrated the beneficial effects of arsenic trioxide (ATO) in the treatment of relapsed acute promyelocytic leukemia (APL). The aim of this review is to discuss the role of ATO in the management of APL. Based on the available clinical evidence, a tentative algorithm is proposed for the treatment of patients who relapse after or are refractory to all trans-retinoic acid-based therapy. Other opportunities for the use of ATO in front-line treatment of APL are also discussed, especially its potential use in patients at high risk of relapse and in those with contraindications to chemotherapy or in whom the amount of chemotherapy should be reduced.


This article has been cited by other articles:


Home page
 MutagenesisHome page
C.-Y. Chai, Y.-C. Huang, W.-C. Hung, W.-Y. Kang, and W.-T. Chen
Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells
Mutagenesis, November 1, 2007; 22(6): 403 - 408.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica, November 1, 2007; 92(11): 1519 - 1532.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. S. Dbaibo, Y. Kfoury, N. Darwiche, S. Panjarian, L. Kozhaya, R. Nasr, M. Abdallah, O. Hermine, M. El-Sabban, H. de The, et al.
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity
Haematologica, June 1, 2007; 92(6): 753 - 762.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Lo-Coco, E. Ammatuna, and M. A. Sanz
Current treatment of acute promyelocytic leukemia
Haematologica, March 1, 2007; 92(3): 289 - 291.
[Full Text] [PDF]

Home page
 Plant Physiol.Home page
D. R. Ellis, L. Gumaelius, E. Indriolo, I. J. Pickering, J. A. Banks, and D. E. Salt
A Novel Arsenate Reductase from the Arsenic Hyperaccumulating Fern Pteris vittata
Plant Physiology, August 1, 2006; 141(4): 1544 - 1554.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. C. Wood, O. E. Salavagionne, B. Mukherjee, L. Wang, A. F. Klumpp, B. A. Thomae, B. W. Eckloff, D. J. Schaid, E. D. Wieben, and R. M. Weinshilboum
Human Arsenic Methyltransferase (AS3MT) Pharmacogenetics: GENE RESEQUENCING AND FUNCTIONAL GENOMICS STUDIES
J. Biol. Chem., March 17, 2006; 281(11): 7364 - 7373.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. A. Sanz
Treatment of Acute Promyelocytic Leukemia
Hematology, January 1, 2006; 2006(1): 147 - 155.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.